AviGenics, Inc. is a bio-pharmaceutical company developing improved and cost-efficient bio-therapeutics for the treatment of cancer, infectious diseases, organ-dysfunction, genetic disorders and autoimmune diseases. The Company’s unique proprietary technology is designed to produce naturally glycosylated bio-therapeutics and allows rapid and efficient product development. Using this technology, AviGenics can achieve commercially feasible levels of production and purification for a wide array of bio-therapeutics.

AviGenics’ proprietary technology can be applied to manufacture multiple categories of bio-therapeutics such as cytokines, human monoclonal antibodies, therapeutic enzymes, and fusion proteins. AviGenics has demonstrated success in using its proprietary technology in a number of key areas, including:

Production of several bio-therapeutics
Bio-therapeutics that feature natural glycosylation
US-FDA approved INDs for two bio-therapeutic products
Safety and efficacy of bio-therapeutic products in clinical trials
Significant capital cost reduction compared to mammalian cell processes